INTSHealthcare · BiotechnologyThe 6 Wall Street analysts covering Intensity Therapeutics, Inc. hold a median 12-month price target of $18 — +259.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Intensity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Momentum (20): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +259.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $7.00 |
| 20 Aug 2025 | Benchmark | Maintains | Speculative Buy | $4.00 → $1.50 |
| 20 Aug 2025 | Benchmark | Maintains | Speculative Buy | — |
| 12 Aug 2025 | Brookline Capital | Upgrade | Buy | — |
| 13 Jan 2025 | Alliance Global Partners | Initiates | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 July 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 16 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 21 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 14 Nov 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 24 Aug 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 18 July 2023 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INTS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 66% of US stocks
Cheaper than 64% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Intensity Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the Q2 2026 earnings call transcript for Intensity Therapeutics, Inc. (INTS), covering the company's quarterly earnings presentation and discussion.
Why it matters — INTS watchers can review management's Q2 2026 commentary from the official earnings call transcript.
Intensity Therapeutics reported second quarter 2026 financial results, with cash and cash equivalents of $9.5 million as of June 30, 2026. The company began activities to resume enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026, restarted patient treatment in the Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer study, and increased business development activities.
Why it matters — This update signals resumed clinical progress across two key trials and a modest cash position, which INTS watchers would track as important catalysts for the company's pipeline.
Intensity Therapeutics announced it will report its second quarter 2026 financial results before the market opens on August 11, 2026, and will hold a conference call at 8AM ET that day to review the results and provide a corporate update.
Why it matters — The upcoming earnings release and conference call will give INTS watchers their latest update on the company's financials and clinical-stage business.
The 6 Wall Street analysts covering Intensity Therapeutics, Inc. have a median 12-month price target of $18, with estimates ranging from $7 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Intensity Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intensity Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Intensity Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +259.7% from the last close, and Ticker Nerd's factor model ranks Intensity Therapeutics, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intensity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $32 over the next 12 months.
Intensity Therapeutics, Inc. returned -38.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Intensity Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative cancer treatments that enhance the effectiveness of conventional therapies.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript". Seeking Alpha published the Q2 2026 earnings call transcript for Intensity Therapeutics, Inc. (INTS), covering the company's quarterly earnings presentation and discussion.
Intensity Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative cancer treatments that enhance the effectiveness of conventional therapies. The company's primary focus is on discovering and advancing novel, proprietary immune-based drug products to combat solid tumors. Utilizing its unique DfuseRxSM technology platform, Intensity Therapeutics integrates chemotherapy with immunotherapy to create a localized treatment that stimulates a systemic, adaptive immune response. This approach aims to increase the overall survival rate of cancer patients while minimizing side effects. Intensity Therapeutics primarily targets the oncology sector, with applications in various cancer types including breast, colorectal, and liver cancers. Highlighted by its ongoing clinical trials, the company plays a significant role in advancing medical research and development in the biotech industry. Intensity Therapeutics Inc. demonstrates a strong commitment to pioneering new frontiers in cancer treatment, contributing significantly to both scientific innovation and patient care within the healthcare market.
CEO Mr. Lewis H. Bender M.A., M.B.A., M.S. · 5 employees · United States · https://intensitytherapeutics.com